Does impaired CFVR LAD predict adverse cardiac outcomes in patients with asymmetric hypertrophic cardiomyopathy?
In patients with HCM, impaired CFVR LAD (≤2) strongly predicts adverse cardiac outcomes, making CFVR PD evaluation redundant for risk stratification.
<0.001), while CFVR PD was not significantly associated with outcome. Conclusions In patients with HCM, impaired CFVR LAD (≤2) is a strong, independent predictor of adverse cardiac outcome. When the aim of testing is HCM risk stratification and CFVR LAD data are available, the evaluation of CFVR PD is redundant.
Tešić et al. (Tue,) studied this question.